HTG Molecular Diagnostics, Inc.
HTGMQ · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $1 | $2 | $1 | $1 |
| % Growth | -57.7% | 95% | -16.1% | – |
| Cost of Goods Sold | $1 | $2 | $1 | $1 |
| Gross Profit | -$0 | $0 | $1 | $0 |
| % Margin | -11.3% | 16.7% | 46.4% | 32% |
| R&D Expenses | $2 | $1 | $2 | $2 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3 | $3 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $5 | $5 | $6 |
| Operating Income | -$5 | -$5 | -$4 | -$6 |
| % Margin | -485.5% | -186.6% | -347.6% | -380.6% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$5 | -$5 | -$5 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$5 | -$5 | -$6 |
| % Margin | -489.6% | -192.4% | -361% | -394.8% |
| EPS | -2.28 | -2.12 | -4.91 | -6.42 |
| % Growth | -7.5% | 56.8% | 23.5% | – |
| EPS Diluted | -2.28 | -2.12 | -4.91 | -6.42 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$4 | -$4 | -$5 |
| % Margin | -467.6% | -181.2% | -334.2% | -367.2% |